Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand
© 2017 Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-li...
محفوظ في:
المؤلفون الرئيسيون: | Lojanapiwat B., Pripatnanont C., Choonhaklai V., Soontornpun S., Sriplakich S., Leewansangtong S., Santi-ngamkun A., Opanuraks J., Kongcharoensombat W., Na-Songkla B., Raksakul W., Predanon C. |
---|---|
التنسيق: | دورية |
منشور في: |
2017
|
الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85012939668&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40714 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand
بواسطة: Bannakij Lojanapiwat, وآخرون
منشور في: (2018) -
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand
بواسطة: Bannakij Lojanapiwat, وآخرون
منشور في: (2018) -
Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort
بواسطة: Jasmine Lim, وآخرون
منشور في: (2020) -
Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison
بواسطة: Tan, P.S., وآخرون
منشور في: (2016) -
Hormonal ablation therapy for metastatic prostatic carcinoma : A review
بواسطة: Sunai Leewansangtong, وآخرون
منشور في: (2018)